Abstract

There is growing evidence on the role of peripheral µ-opioid receptors (MORs) in analgesia and analgesic tolerance. Opioid analgesics are the mainstay in the management of moderate to severe pain, and their efficacy in the alleviation of pain is well recognized. Unfortunately, chronic treatment with opioid analgesics induces central analgesic tolerance, thus limiting their clinical usefulness. Numerous molecular mechanisms, including receptor desensitization, G-protein decoupling, β-arrestin recruitment, and alterations in the expression of peripheral MORs and microbiota have been postulated to contribute to the development of opioid analgesic tolerance. However, these studies are largely focused on central opioid analgesia and tolerance. Accumulated literature supports that peripheral MORs mediate analgesia, but controversial results on the development of peripheral opioid receptors-mediated analgesic tolerance are reported. In this review, we offer evidence on the consequence of the activation of peripheral MORs in analgesia and analgesic tolerance, as well as approaches that enhance analgesic efficacy and decrease the development of tolerance to opioids at the peripheral sites. We have also addressed the advantages and drawbacks of the activation of peripheral MORs on the sensory neurons and gut (leading to dysbiosis) on the development of central and peripheral analgesic tolerance.

Highlights

  • The present consensus is that all opioid agonists used in clinical practice produce analgesia primarily mediated by μ-opioid receptors (MORs) located within the brain and spinal cord along the pain transmission pathways

  • The number of MOR agonists with limited central nervous system (CNS) penetration and displaying peripheral analgesia have been increasing over the years, but they have not been proven so far to be of clinical value [43,52,66,67]

  • Methylnaltrexone, a peripherally acting opioid antagonist, abrogated the analgesic tolerance when co-administered with morphine, without diminishing the analgesic effect of morphine, in different pain models. These results indicate that the systemic co-administration of peripherally acting opioid antagonists with opioid analgesics that readily penetrate into the CNS might be a new clinical approach for the prevention of central analgesic tolerance development [114]

Read more

Summary

Introduction

The present consensus is that all opioid agonists used in clinical practice produce analgesia primarily mediated by μ-opioid receptors (MORs) located within the brain and spinal cord along the pain transmission pathways. The growing evidence on the existence of functional peripheral ORs, MORs has initiated research efforts to develop opioid analgesics with limited CNS penetration in order to gain analgesia free of the central unwanted side effects [2,26,32,33,34,35,36,37,38,39]. The number of MOR agonists with limited CNS penetration and displaying peripheral analgesia have been increasing over the years, but they have not been proven so far to be of clinical value [43,52,66,67] These results may initiate further studies to examine the development of peripheral analgesic tolerance, since most research has been focused on the evaluation of the central opioid analgesic tolerance.

Examples
Effect
Peripheral Opioid Analgesia and Tolerance in Animal Neuropathic Pain Models
Main Findings
The Consequence of MORs Activation on Primary Sensory Neurons
The Role of MORs in the Gut Microbiota
Summary and Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call